FDA Approves Oral Vumerity™ (Diroximel Fumarate), Similar to Tecfidera®, for Relapsing MS

Updated 11/17/19 with cost information
SUMMARY
  • The U.S. Food and Drug Administration has approved Vumerity™ (diroximel fumarate, Biogen and Alkermes plc) as an oral disease-modifying therapy for people with relapsing forms of MS.
  • Relapsing forms of MS includes people with clinically isolated syndrome (an initial episode of neurological symptoms), relapsing-remitting MS, and active secondary progressive MS. People with active secondary progressive MS have had progression of disability but still experience acute relapses or new MRI activity.
  • Vumerity is similar to dimethyl fumarate (Tecfidera,® Biogen) but has a distinct chemical structure that has been shown to have fewer reported gastrointestinal side effects than Tecfidera.
  • This approval provides another treatment option for people living with relapsing forms of MS and specifically includes people with secondary progressive MS who are continuing to experience active disease.


Full Text: https://www.nationalmssociety.org/Ab...s&utm_content=